Sex: F
Vaccine: COVID19
Symptoms: Vision blurred
Clinical narrative: Arm was really red; Had a rash on the arm; Arm was hot to the touch; Swollen arm; fluctuations on her heart rate; a fast heart beating; saw everything blurry; a feeling that she was going to faint; Anxiety; panick attacks; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. Other Case identifier(s): MOD22-026839 (Moderna).  A female patient received BNT162b2 (BNT162B2), on 15Oct2021 as dose 3 (booster), single (Lot number: FF2590) for covid-19 immunisation. The patient's relevant medical history included: "Allergies: tapes" (unspecified if ongoing); "Allergies: latex" (unspecified if ongoing); "Allergies: Penicillin" (unspecified if ongoing); "Allergies: Soap" (unspecified if ongoing); "Allergies: Steroid injections" (unspecified if ongoing); "Arm was really red" (unspecified if ongoing), notes: Dose 1, Dose 2; "Had a rash on the arm" (unspecified if ongoing), notes: Dose 1, Dose 2; "Arm was hot to the touch" (unspecified if ongoing), notes: Dose 1, Dose 2; "Swollen arm" (unspecified if ongoing), notes: Dose 1, Dose 2; "fluctuations on her heart rate" (unspecified if ongoing), notes: Dose 1, Dose 2; "a fast heart beating" (unspecified if ongoing), notes: Dose 1, Dose 2; "saw everything blurry" (unspecified if ongoing), notes: Dose 1, Dose 2; "a feeling that she was going to faint" (unspecified if ongoing), notes: Dose 1, Dose 2; "Anxiety" (unspecified if ongoing), notes: Dose 1, Dose 2; "panic attacks" (unspecified if ongoing), notes: Dose 1, Dose 2. Concomitant medication(s) included: ACICLOVIR; ATORVASTATIN; CALCIUM; HYDROCHLOROTHIAZIDE; IBUPROFEN; OMEPRAZOLE; PROBIOTICS; VITAMIN D [VITAMIN D NOS]; VITAMIN E [VITAMIN E NOS]; VITAMIN C [ASCORBIC ACID]. Past drug history included: Gabapentin, reaction(s): "Allergies: Gabapentin". Vaccination history included: BNT162b2 (Dose Number: 1 , Manufacturer: Pfizer , Lot number. GN6206 , Dose , Date administered: 08Mar2021), administration date: 08Mar2021, for COVID-19 immunization; BNT162b2 (Dose Number: 2 , Manufacturer: Pfizer , Lot number. GN6204 , Dose , Date administered: 29Mar2021), administration date: 29Mar2021, for COVID-19 immunization. The following information was reported: ERYTHEMA (non-serious), outcome "recovered", described as "Arm was really red"; RASH (non-serious), outcome "recovered", described as "Had a rash on the arm"; FEELING HOT (non-serious), outcome "recovered", described as "Arm was hot to the touch"; PERIPHERAL SWELLING (non-serious), outcome "recovered", described as "Swollen arm"; HEART RATE IRREGULAR (non-serious), outcome "recovered", described as "fluctuations on her heart rate"; HEART RATE INCREASED (non-serious), outcome "recovered", described as "a fast heart beating"; VISION BLURRED (non-serious), outcome "recovered", described as "saw everything blurry"; DIZZINESS (non-serious), outcome "recovered", described as "a feeling that she was going to faint"; ANXIETY (non-serious), outcome "recovered"; PANIC ATTACK (non-serious), outcome "recovered", described as "panick attacks". Relevant laboratory tests and procedures are available in the appropriate section.  Additional information: Patient not had COVID, test or diagnosis. Hx was not relating to mentioned AE and both Acute and Chronic illnesses at the time of vaccination. Other vaccines were not given within 1 month prior to Moderna COVID-19 vaccine. Arm was really red. Had a rash on the arm. Arm was hot to the touch. Swollen arm. Arm was red for 10 days. She experienced fluctuations on her heart rate and a fast heart beating. Had some episodes were she saw everything blurry, she had a feeling that she was going to faint, felt she was going to pass out. Anxiety, panick attacks. Couldn't control what was happening. AE was not caused patient to seek medical care (office visit, urgent care, ER, hospitalized). Have symptoms improved. patient received elasomeran (MODERNA COVID-19 VACCINE), on 22Apr2022 as dose 4 (booster), single (Lot number: 002M21A) for covid-19 immunization.  No follow-up attempts are possible. No further information is expected.